NeuroClues
Description
NeuroClues (https://neuroclues.com/) is a MedTech startup aiming to become the brain’s stethoscope. Our platform leverages eye-tracking technology to provide non-invasive, simple, and robust biomarkers to detect cognitive and neurological disorders, like Parkinson's Disease, 10x faster than current methodologies.
Highlights:
- Used with Patients at the Paris Brain Institute and included in the biggest Parkinson Cohort in France with 500 subjects
- Published in posters showcasing the potential for neuroClues to diagnose and prognose patients. We unveiled a new biomarker (MII) that could support early detection and differential diagnosis up to 5 years in advance allowing increasing patient’s QoL and modify the disease progression. https://neuroclues.com/sfn23-poster-evidence-exogenous-input-superior-colliculus-source-saccadic-inhibition/
- Traction from top tier KOL and institutions like: NYU, Johns Hopkins, Cleveland, La Pitié Salpétrière, Rothschild, Radboud and 40+ others
- Target 10M patients by 2032 leading to 116M ARR in a 1.5B€ SOM
- Raised 12M€ to date + 6.5M€ (to be invested) from EIC accelerator, the biggest deep tech fund with 40B€ under management.
- Build a team of 25+ MedTech experts and entrepreneurs (https://vimeo.com/688353955/99512f88f1)
We are raising a Serie A round of 10M€ end 2024 for which we are looking for a lead.
